Cell Source

Cell Source EBITDA per Employee

EBITDA per Employee of Cell Source (CLCS) as of Oct 19, 2026.

EBITDA per Employee

-USD

Last updated:

EBITDA per Employee of Cell Source is 2026 - USD. EBITDA per Employee of Cell Source was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Source Stock analysis

What does Cell Source do? Cell Source Inc., based in New York City, operates in the Health Care sector as a biotechnology company specializing in immunotherapy. The company, listed on 14 January 2014, focuses on developing Veto Cell technology, an immune tolerance biotechnology enabling selective immune response blocking. Its lead product targets allogeneic hematopoietic stem cell transplantation, supporting haploidentical transplants with mild conditioning. The pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and non-malignant disorders. The firm holds a wholly owned subsidiary, Cell Source Limited. Cell Source is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Source stock

On Eulerpool you can find the complete historical development of EBITDA per Employee Cell Source since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Cell Source historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cell Source

All Key Metrics — Cell Source